Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q4 2025 | ~2026-04-01 | $0.0800 |
| Q3 2026 | ~2026-03-31 | $0.0800 |
| Q2 2025 | ~2025-12-31 | $0.0800 |
| Q1 2025 | ~2025-09-30 | $0.0800 |
| Q4 2024 | ~2025-04-01 | $0.0800 |
| Q3 2025 | ~2025-03-31 | $0.0800 |
| Q2 2024 | ~2024-12-31 | $0.0800 |
| Q1 2024 | ~2024-09-30 | $0.0800 |
| Q3 2024 | ~2024-03-31 | $0.0800 |
| Q2 2023 | ~2023-12-31 | $0.0800 |
| Q1 2023 | ~2023-09-30 | $0.0800 |
| Q3 2023 | ~2023-03-31 | $0.0800 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The… company's broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. The company operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy, and includes proteomic analytical tools for protein analysis. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products including controls, calibrators, diagnostic assays, tissue-based in-situ hybridization assays, instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits. The company was founded in 1976 as Research and Diagnostic Systems, Inc. and became publicly traded in 1985 through a merger with Techne Corporation.
- Name
- Bio-Techne Corporation
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman · President and Chief Executive Officer
- Employees
- 3,800 as of 2025-06-30
- IPO Date
- 2006-10-27
- Phone
- (612) 379-8854
- Address
- 614 McKinley Place N.E., Minneapolis, MN 55413
- Website
- www.bio-techne.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Joseph D. Keegan | Director | — |
| John L. Higgins | Director | — |
| Julie L. Bushman | Director | — |
| Robert V. Baumgartner | Chair of the Board | — |
| Kim Kelderman | President and Chief Executive Officer | — |
Latest News
- 2026-04-21
- 2026-04-17
- 2026-04-16
- 2026-04-15
- 2026-04-14
- 2026-04-13
- 2026-04-13
- 2026-04-10